At the ASH 2023 Conference held in December, Jane Liesveld, a physician from the University of Rochester Medical Center, shared results from a collaboration concerning the IDH2 gene mutation. Watch the video below or continue reading to hear more about Dr. Liesveld's important research.
The isocitrate dehydrogenase 2 (IDH2) mutation impairs a cell’s immune system and its macrophages (a type of white blood cell) that is necessary for eliminating diseased cells. This allows the cancerous cells to continue to grow in the bone marrow and lead to inflammatory changes. The IDH mutation increases in frequency with age and can lead to greater implications than previously understood.
This mutation occurs in 15%-20% of AML patients and has an affect on how genes are expressed. To better understand this mutation, murine cells were examined for their manifestation and survival. This collaboration discovered that when this mutation is present, MDS often evolves into AML. It also examined how AML cells break down (metabolize) in the body and how this mutation affects stem cells. More research is needed to understand how IDH2 genes grow and produce energy (metabolic substrates).
This abstract study was initiated to begin to better understand this gene mutaiton and its affects on the AML cell. Targeting IDH2 is a future treatment goal.
See these articles for further information on IDH2:
Understanding the IDH1 and IDH2 mutations
Recent Drug Approvals For AML Part 2: IDH Inhibitors
Common Genetic Mutations Found In AML
At HealthTree, we believe that patients are powerful and have an opportunity to contribute to research in an incredibly unique way. HealthTree Cure Hub empowers patients with the knowledge to actively participate in their health journeys while providing researchers with valuable insights from real-world experiences. HealthTree Cure Hub connects patients and researchers to not only accelerate the development of innovative treatments but also lays the foundation for a future where more educated patients and research leads to more effective and personalized cures. Visit HealthTree Cure Hub today to become an active participant in your care and contribute your unique experience to researchers to move closer to a cure.
For assistance setting up your HealthTree Cure Hub account, reach out to our patient navigation team by phone: 1-800-709-1113 or email: support@healthtree.org
At the ASH 2023 Conference held in December, Jane Liesveld, a physician from the University of Rochester Medical Center, shared results from a collaboration concerning the IDH2 gene mutation. Watch the video below or continue reading to hear more about Dr. Liesveld's important research.
The isocitrate dehydrogenase 2 (IDH2) mutation impairs a cell’s immune system and its macrophages (a type of white blood cell) that is necessary for eliminating diseased cells. This allows the cancerous cells to continue to grow in the bone marrow and lead to inflammatory changes. The IDH mutation increases in frequency with age and can lead to greater implications than previously understood.
This mutation occurs in 15%-20% of AML patients and has an affect on how genes are expressed. To better understand this mutation, murine cells were examined for their manifestation and survival. This collaboration discovered that when this mutation is present, MDS often evolves into AML. It also examined how AML cells break down (metabolize) in the body and how this mutation affects stem cells. More research is needed to understand how IDH2 genes grow and produce energy (metabolic substrates).
This abstract study was initiated to begin to better understand this gene mutaiton and its affects on the AML cell. Targeting IDH2 is a future treatment goal.
See these articles for further information on IDH2:
Understanding the IDH1 and IDH2 mutations
Recent Drug Approvals For AML Part 2: IDH Inhibitors
Common Genetic Mutations Found In AML
At HealthTree, we believe that patients are powerful and have an opportunity to contribute to research in an incredibly unique way. HealthTree Cure Hub empowers patients with the knowledge to actively participate in their health journeys while providing researchers with valuable insights from real-world experiences. HealthTree Cure Hub connects patients and researchers to not only accelerate the development of innovative treatments but also lays the foundation for a future where more educated patients and research leads to more effective and personalized cures. Visit HealthTree Cure Hub today to become an active participant in your care and contribute your unique experience to researchers to move closer to a cure.
For assistance setting up your HealthTree Cure Hub account, reach out to our patient navigation team by phone: 1-800-709-1113 or email: support@healthtree.org
about the author
Lisa Foster
Lisa Foster is a mom of 3 daughters, a puzzle lover, writer and HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.